天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Analytical Chemistry>Standard>Pharmaceutical Impurity Reference Standards>Roflumilast N-oxide
Roflumilast N-oxide
  • Roflumilast N-oxide

Roflumilast N-oxide NEW

Price $30 $44 $68
Package 1mg 2mg 5mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: Roflumilast N-oxide CAS No.: 292135-78-5
Purity: 99.65% Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameRoflumilast N-oxide
DescriptionRoflumilast N-oxide is an inhibitor of PDE type 4.
Cell ResearchA549 cells are washed and cultured overnight in serum-free F-12 K medium supplemented with antibiotics, L-glutamine and HEPES. The starved cells are incubated with Neutrophil elastase (NE) for 30 min or vehicle (PBS), washed with PBS and then cultured in serum free F-12 K. After stimulation, cell supernatants are collected at 24 h (for cytokine measurements) and cell pellets are collected after 2 h (for mRNA expression analysis). Alternatively, A549 cells are pre-incubated for 2 h with Roflumilast N-oxide (RNO) (at 0.1 μM, 0.3 μM and 1 μM), vehicle (DMSO 0.01%) prior to the addition of NE. All experiments are performed in serum-free medium in triplicate and are repeated at least three times. At the end of the incubation period, culture supernatants are harvested and stored at -80°C until further analysis
Animal ResearchAt 7 weeks of age, 16 h fasting mice receive a single oral dose of vehicle (4% methocel) or 10 mg/kg Roflumilast-N-oxide, and a glucose bolus of 2 g/kg body weight is co-administered as a physiological initiator for glucagon-like peptide-1 (GLP-1) secretion. Plasma GLP-1 is analyzed 60 min before, and 10 and 60 min after administration of Roflumilast-N-oxide and glucose. The effect of Roflumilast-N-oxide on plasma GLP-1 is also investigated in the absence of the glucose bolus
In vitroRoflumilast N-oxide, at a concentration of 2 nM, partially counteracts the effects of cigarette smoke extract (CSE)-induced epithelial to mesenchymal transition (EMT) in WD-HBEC cells in vitro. It restores 45% of E-cadherin transcript expression adversely affected by CSE and suppresses the expression of collagen type I. Additionally, it protects the epithelial cell phenotype from CSE-induced alterations by co-incubation and partially mitigates the nuclear translocation of β-catenin through pre-incubation.
In vivoA single administration of Roflumilast N-oxide at a dose of 10 mg/kg in db/db mice significantly increases plasma glucagon-like peptide-1 (GLP-1) levels by fourfold. Continuous treatment with 3 mg/kg of this compound effectively hinders disease progression in these mice, eliminating the rise in blood glucose, halving the rise in HbA1c, and doubling the level of fasted serum insulin compared to the control group, alongside preserving the structure of pancreatic islets. Furthermore, Roflumilast N-oxide enhances insulin release from primary islets stimulated by forskolin and demonstrates more potent glucose-lowering properties than its parent compound.
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility InformationDMSO : 50 mg/mL (119.27 mM)
KeywordsPhosphodiesterase (PDE) | Roflumilast N oxide | Roflumilast Noxide | Inhibitor | Roflumilast N-oxide | inhibit
Inhibitors RelatedTheophylline monohydrate | Roflumilast | Theobromine | Apremilast | Isoprenaline hydrochloride | Indomethacin | Icariin | Theophylline | Vardenafil hydrochloride | Doxofylline
Related Compound LibrariesBioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Human Metabolite Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/5mg
VIP3Y
TargetMol Chemicals Inc.
2024-11-19
$0.00/1g
VIP1Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2024-09-29
$25.00/1ASSAYS
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
2024-11-19
$8.00/1kg
VIP2Y
Henan Fengda Chemical Co., Ltd
2024-04-25
  • Since: 2011-01-07
  • Address: 36?Washington?Street, Wellesley?Hills
INQUIRY